Search
ORIGINS is now offering telehealth appointments for the paediatric assessment at the one- and three-year timepoints
Find answers to frequently asked questions about ORIGINS.
Accessing the ORIGINS cohort, database or biological samples involves a process of review and approval.
A list of organisations that currently collaborate with ORIGINS.
Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in B-cell malignancies, but its application in acute myeloid leukemia (AML) and renal cell carcinoma (RCC) remains challenging due to the lack of ideal target antigens. CD70 is highly expressed on AML and RCC tumor cells, while its expression in normal tissues is largely restricted to activated lymphocytes, making it a promising immunotherapeutic target.